If your company has experience with an unnecessary, duplicative or frustrating hurdle in the course of doing business, OBIO wants to know. Please tell us what the challenges are and how they impact your company. As part of OBIO’s engagement with the provincial government, the health science industry’s recommendations on red tape or regulatory burdens that can be addressed are being sought by the Government of Ontario.
On May 13th, OBIO hosted the 2019 Queen’s Park Health Science Industry Showcase which attracted over 100 attendees, including Ministers, MPPs, government officials and health science industry leaders who came to see the latest in health care innovation from our displaying companies.
The Ontario Bioscience Innovation Organization (OBIO®) today released its latest report, ‘Achieving Impact Through Adoption of Innovative Health Technologies: Establishing Early Adopter Health Organizations as an Accelerator for Economic Growth in Ontario’, which describes an early adopter model to facilitate the evaluation and adoption of innovative health technologies in Ontario health organizations.
OBIO® (Ontario Bioscience Innovation Organization) is proud to announce the success of the 2019 Niagara Investment Summit on February 20-22, 2019. The 2019 Niagara Investment Summit featured over 30 of Canada’s most promising innovative health science companies and more than 30 US and global investors and VCs.
OBIO is proud to announce the opening of the 2019 Niagara Investment Summit in Niagara-on-the-Lake, Ontario, on February 21-22, 2019. The 2019 Niagara Investment Summit will feature over 30 of Canada’s most promising innovative health science companies meeting with more than 30 US and global investors and VCs in Niagara-on-the-Lake to propel investment in Canada’s health science industry.
Composed of a series of four guides, the OBIO Talent Toolkit stems from the success of the OBIO Health to Business Bridge (H2BB™) program which addresses an expressed need for more talent in the health science industry.
OBIO’s report, Realizing the Promise of Health Care Innovation: Increasing Value for the Patient, Health System and Economy, was published in 2013 and is a product of the Ontario Bioscience Economic Strategy Team (OBEST®), an initiative launched by OBIO to address the challenges faced by Ontario’s human health technology and bioscience industry.
Bridging the Talent Gap reports on the unique value of OBIO’s Health to Business Bridge (H2BB) business internship program. This report describes how H2BB addresses the challenge of pulling top talent into Ontario’s health science industry to address the talent gap identified by 96% of Ontario’s health science company CEOs.
The “Tackling the Anchor Company Challenge Summit”, assembled industry, academic, government and investment leaders committed to working together to create a mandate of action for anchoring health science companies in Ontario.
In 2017, the Ontario Bioscience Innovation Organization convened a working group (‘OBIO Tax Policy Working Group’, OTPWG) of health science industry leaders and tax experts from academia and the private sector to examine Canada’s tax incentives and their effectiveness in stimulating growth in the health science industry.
"The Ontario Bioscience Innovation Organization (OBIO) strongly believes that the supply chain of the future must incorporate a formal approach to creating pathways for the adoption and procurement of innovation, to benefit the people of Ontario from both a health and economic perspective."
2016 has already been a productive year for OBIO as we push forward on our advocacy efforts, expand our Health Science networks and partnerships and continue to provide access to capital for Ontario Health Science companies in order for them to reach the next level.
Christine Sarkisian will be retiring this week from her position as Trade Commissioner, Life Sciences Business Development. For nearly 30 years at the Consulate General of Canada in Boston she has been instrumental in working with and helping Canadian entrepreneurs on their path to commercialization.
Winterlight Labs announced it is developing vocal biomarkers for monitoring disease progression in frontotemporal dementia patients in collaboration with Alector, a biotechnology company developing therapeutics for neurodegeneration.